Ellagic acid (EA): A Green Multi-Target Weapon Reducing Oxidative Stress and Inflammation Thus Preventing and Ameliorating Alzheimer Disease (AD) Condition

vivo ETs are rather not absorbed, while providing mainly ellagic acid (EA), which due to its trivial water-solubility, first pass effect, metabolism in the intestine to give UROs, or irreversible binding to cellular DNA and proteins is in turn very low bioavailable, thus failing as therapeutic in vivo. Up-to-day, only UROs have confirmed the beneficial effect demonstrated in vitro, by reaching tissues to the extent necessary for having therapeutic outcomes. Unfortunately, upon administration of food rich in ETs or ETs and EA, UROs formation is affected by extreme interindividual variability that renders them unreliable as novel clinically usable drugs. Large attention has been therefore paid specifically to multitarget EA, which is incessantly investigated as such or nanotechnologically manipulated to be a potential “lead compound” with protective action towards AD. A brief overview of the multi-factorial and multi-target aspects that characterize AD, and polyphenols activity respectively, as well as of the traditional and/or innovative clinical treatments available to treat AD constitutes the opening of this work. Upon focus on the pathophysiology of OS, and on EA chemical features and mechanisms leading to its antioxidant activity, an all-round updated analysis on the current EA-rich foods and EA involvement in the field of AD has been provided. The possible clinical usage of EA to treat AD has been shown reporting results by its applications in vivo and clinical trials. A critical view about the need for a more extensive use of the most rapid diagnostic methods to detect AD from its early symptoms has also been included in this work.